Prnewswire·2025-11-04 21:01Core Insights - PTC Therapeutics reported a strong third quarter for 2025, driven by the global launch of Sephience, which is expected to become the standard of care for individuals with PKU [1][4][5] Financial Performance - Total revenue for Q3 2025 was $211 million, an increase from $196.8 million in Q3 2024 [5] - Sephience generated $19.6 million in revenue during Q3 2025, with $14.4 million from the US and $5.2 million from international markets [5] - The DMD franchise contributed $85.9 million in revenue, with Translarna at $50.7 million and Emflaza at $35.2 million [5] - Royalty revenue from Evrysdi was $70.8 million for Q3 2025, up from $61.4 million in Q3 2024 [5] Expense Overview - GAAP R&D expenses were $100.2 million for Q3 2025, down from $161.4 million in Q3 2024 [5] - GAAP SG&A expenses increased to $84 million in Q3 2025 from $73.5 million in Q3 2024 [5] - Non-GAAP R&D expenses were $91 million, while non-GAAP SG&A expenses were $73.8 million for Q3 2025 [5] Net Income and Cash Position - The company reported a net income of $15.9 million for Q3 2025, a significant improvement from a net loss of $106.7 million in Q3 2024 [5] - Cash, cash equivalents, and marketable securities totaled $1.688 billion as of September 30, 2025, compared to $1.140 billion at the end of 2024 [5] Future Guidance - PTC anticipates full-year 2025 total revenue between $750 million and $800 million [4][8] - The company is planning additional marketing authorization reviews for Sephience, including in Japan, with a decision expected in Q4 2025 [5]